Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Not applicable Interventional

Non-healing Diabetic Foot Ulcers Treated With Standard Care With or Without BR-AM

ClinicalTrials.gov ID: NCT06565156

Public ClinicalTrials.gov record NCT06565156. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 7, 2026, 2:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective, Multicenter, Randomized, Controlled Trial of Non-healing Diabetic Foot Ulcers Treated With Standard Care With or Without BR-AM

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This trial is a multicenter, randomized, controlled study designed to evaluate the safety and efficacy of BioREtain® Amniotic Membrane (BR-AM) plus standard of care versus standard of care only in the treatment of diabetic foot ulcers. The trial design will control potential variables that may affect the outcome between the treatment group and the control group by standardizing the requirements for debridement, wound dressings, and offloading. Weekly subject visits will help monitor compliance in wound care and off-loading, as well as to document when wound closure is achieved. The study will also implement the use of an electronic imaging and measurement device using a standardized protocol to ensure the measuring of the wound surface area and volume is accurate, highly reproducible, and minimally variable. There will also be a crossover treatment phase for those patients that were relegated to standard care only. After their 12-week standard of care treatment phase and for only those subjects that did not achieve complete wound closure, will be allowed to crossover for an additional 12 weeks of treatment with the BR-AM product following the protocol and procedures set forth within this document.

Study identification

NCT ID
NCT06565156
Recruitment status
Completed
Study type
Interventional
Phase
Not applicable
Lead sponsor
BioStem Technologies
Industry
Enrollment
72 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 27, 2024
Primary completion
Nov 13, 2025
Completion
Apr 29, 2026
Last update posted
Aug 11, 2026

2024 – 2026

United States locations

U.S. sites
17
U.S. states
10
U.S. cities
17
Facility City State ZIP Site status
Site 17 Guntersville Alabama 35976
Site 22 Mesa Arizona 85206
Site 25 Tucson Arizona 85723
Site 19 Palmdale California 93551
Site 02 San Francisco California 94115
Site 01 Vista California 92081
Site 27 Coral Gables Florida 33134
Site 20 Deerfield Beach Florida 33442
Site 28 DeLand Florida 32720
Site 23 Springfield Illinois 62704
Site 18 Boston Massachusetts 02118
Site 26 Detroit Michigan 48201
Site 16 Lake Success New York 11042
Site 15 Chapel Hill North Carolina 27599
Site 29 Brownsville Texas 78520
Site 21 Burleson Texas 76028
Site 24 San Antonio Texas 78229

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06565156, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 11, 2026 · Synced Sep 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06565156 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →